ID   DH978
AC   CVCL_IV32
DR   Wikidata; Q54831067
RX   PubMed=7882347;
RX   PubMed=8515068;
CC   Sequence variation: Mutation; HGNC; 1784; CDKN1A; Simple; p.Phe63Leu (c.189C>A); Zygosity=Heterozygous (PubMed=7882347).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Cell type: B-cell; CL=CL_0000236.
DI   NCIt; C27694; EBV-related Burkitt lymphoma
DI   ORDO; Orphanet_543; Burkitt lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
CA   Cancer cell line
DT   Created: 03-03-17; Last updated: 02-05-24; Version: 8
//
RX   PubMed=7882347;
RA   Bhatia K.G., Fan S.-J., Spangler G., Weintraub M., O'Connor P.M.,
RA   Judde J.-G., Magrath I.T.;
RT   "A mutant p21 cyclin-dependent kinase inhibitor isolated from a
RT   Burkitt's lymphoma.";
RL   Cancer Res. 55:1431-1435(1995).
//
RX   PubMed=8515068; DOI=10.4049/jimmunol.150.12.5418;
RA   Jain V.K., Judde J.-G., Max E.E., Magrath I.T.;
RT   "Variable IgH chain enhancer activity in Burkitt's lymphomas suggests
RT   an additional, direct mechanism of c-myc deregulation.";
RL   J. Immunol. 150:5418-5428(1993).
//